Other genetic alterations are meaningful for the molecular characterization of different types of brain tumors, including mutation in the promoter of telomerase reverse transcriptase (TERT) for oligodendroglioma, the v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) V600E mutation for non-diffuse glioma, and v-rel avian reticuloendotheliosis viral oncogene homolog A (RELA) fusion for supratentorial ependymomas (11, 12). This evidence concerns the gene TERT and brain neoplasm.